TY  - JOUR 
AU  - Mateos Manteca, María Victoria
AU  - Hernández, Miguel-Teodoro
AU  - Giraldo, Pilar
AU  - De la Rubia, Javier
AU  - De Arriba, Felipe
AU  - López Corral, Lucía
AU  - Rosiñol, Laura
AU  - Paiva, Bruno
AU  - Palomera, Luis
AU  - Bargay, Joan
AU  - Oriol, Albert
AU  - Prósper, Felipe
AU  - López, Javier
AU  - Olavarría, Eduardo
AU  - Quintana, Nuria
AU  - García, José-Luis
AU  - Bladé, Joan
AU  - Lahuerta, Juan José
AU  - San Miguel Izquierdo, Jesús Fernando
PY  - 2013
UR  - http://hdl.handle.net/10366/154298
AB  - [EN]For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early intervention.
In this randomized, open-label, phase...
LA  - eng
PB  - NEJM Group
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Dexamethasone
KW  - Disease Progression
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Induction Chemotherapy
KW  - Lenalidomide
KW  - Male
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - Risk
KW  - Survival Rate
KW  - Thalidomide
KW  - Disease Progression
KW  - Aged
KW  - Adult
KW  - Induction Chemotherapy
KW  - Follow-Up Studies
KW  - Humans
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - Risk
KW  - Thalidomide
KW  - Dexamethasone
KW  - Survival Rate
TI  - Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma
DO  - 10.1056/NEJMoa1300439
T2  - The New England journal of medicine
VL  - 369
M2  - 438
ER  -